Business
Simulations Plus Highlights Platform Innovation and Strategic Direction at 2026 Investor Day
RESEARCH TRIANGLE PARK, N.C., January 21, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today hosted its 2026 Virtual Investor Day, outlining how the Company is advancing an integrated, AI-enabled platform to support the evolving needs of the drug development industry and its regulators.
About this update from Simulations Plus, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/85909ee4dc859c5ce904efe895c2e9d3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QqbWucHCNsarL.Gr4YCVug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/85909ee4dc859c5ce904efe895c2e9d3","width":480,"height":480}},"lazy":false},{"type":"text","content":"Showcases platform momentum, strategic priorities, and long-term value creation outlook","length":87,"tagName":"p","attribs":{}},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., January 21, 2026--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today hosted its 2026 Virtual Investor Day, outlining how the Company is advancing an integrated, AI-enabled platform to support the evolving needs of the drug development industry and its regulators.","length":467,"tagName":"p"},{"type":"text","content":"The Investor Day presentation focused on how Simulations Plus is driving innovation and leading meaningful change across the drug development lifecycle—pairing its long-standing scientific reputation with modern cloud and AI capabilities, while maintaining clear strategic direction.","length":283,"tagName":"p"},{"type":"text","content":""Our industry is at an inflection point," said Shawn O’Connor, Chief Executive Officer of Simulations Plus. "Scientific complexity is increasing, regulatory expectations are evolving, and our clients are under pressure to move faster without compromising rigor. Our strategy is intended to address these challenges by combining trusted science with modern, integrated technology—so teams can make better decisions with confidence."","length":451,"tagName":"p"},{"type":"text","content":"Executive leadership discussed industry dynamics shaping pharmaceutical R&D, including increasing scientific complexity, rising expectations for in silico evidence, and regulatory momentum around model-informed drug development (MIDD), non-animal methodologies (NAMs), and responsible use of AI. The Company highlighted its alignment wi...